Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

OBJECTIVES: SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA). The open-label extension period evaluated long-term efficacy, safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Stasiuk, Barbara, Hilt, Joanna, Mosterova, Zdenka, Cheong, Soo Yeon, Ghil, Jeehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705842/
https://www.ncbi.nlm.nih.gov/pubmed/28794078
http://dx.doi.org/10.1136/annrheumdis-2017-211591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705842/
https://www.ncbi.nlm.nih.gov/pubmed/28794078
http://dx.doi.org/10.1136/annrheumdis-2017-211591

Ejemplares similares